The Politics of Small Boards
Governance literature tends to treat the board as an institution — a set of roles, responsibilities, and processes that function according to formal rules. The reality inside a five-person venture-backed biopharma board is considerably messier. It is a small room populated by individuals who have strong opinions, competing institutional interests, personal histories with each other, and relationships to the CEO and to the company that are rarely as neutral as the governance documents imply.
In a large public company board, interpersonal dynamics are real but partially buffered by size and process. There are enough directors that no single relationship dominates, enough committees that work can be distributed, and enough formality that the institution has some insulation from the personalities within it.
In a small biopharma board, none of those buffers exist. A grudge between two directors changes the character of every meeting they both attend. An alliance between an investor-director and the CEO forecloses certain governance conversations before they begin. A director who has decided, for whatever reason, to undermine a fellow director's credibility will find no shortage of opportunity to do so in a room where every voice carries significant weight. The politics of small boards are not a peripheral concern — they are a central governance challenge that most board members are poorly prepared to navigate.
The Structural Sources of Small-Board Politics
Understanding where the politics come from makes it possible to manage them more effectively.
The most fundamental source is the concentration of institutional interests. In a venture-backed biopharma board, the investor-directors are not neutral governance participants. They are representatives of funds with specific financial positions in the company, specific timelines driven by fund life cycles, and specific preferences about exit strategy, burn rate, and risk tolerance. When two investor-directors represent funds whose interests are not fully aligned — one early investor whose position is deeply in the money and another later investor whose return depends on a much higher exit price — they are not simply two directors with different views. They are two institutional interests in structured tension, and that tension will shape every strategic discussion the board has.
The second source is the asymmetry of information and relationship. The CEO has a working relationship with each board member individually, but the board members' relationships with each other are far thinner. In a company that meets formally six times a year, directors may have relatively little direct exposure to each other outside of board contexts. This means that the CEO is often the most connected node in the board's relational network — a position that creates significant informal influence over board dynamics, regardless of the formal governance structure.
The third source is history. Small biopharma boards often include people who have worked together before — on other boards, in prior companies, in investment relationships. These prior histories carry emotional residue that surfaces in board dynamics without being named. A director who was burned in a prior transaction involving a fellow board member will not announce that history, but it will shape how they engage with that person's proposals, how much credit they extend when things go wrong, and how they interpret ambiguous situations.
The Most Common Patterns — and What They Cost
The investor alliance. When two investor-directors are aligned — either because their funds are co-investors with shared interests or because they have a prior relationship that creates personal affinity — they can effectively control the board's agenda and outcomes without formally constituting a majority. They coordinate before meetings, they support each other's positions in discussion, and they create a dynamic in which dissent from other directors feels futile. Independent directors who recognize this pattern often disengage — not visibly, but in ways that progressively reduce the board's diversity of perspective and the quality of its governance.
The CEO-director alliance. A CEO who has cultivated a strong personal relationship with one or more directors — often the directors who championed their hiring or who have worked with them in prior contexts — has a meaningful informal advantage in any situation where board judgment is needed. The allied director will interpret ambiguous performance charitably, will carry the CEO's preferred framing into discussions where the CEO is not present, and will be less willing to raise concerns that might damage the relationship. This is not necessarily intentional. Personal relationships create genuine affinity, and that affinity shapes judgment in ways that are often invisible to the person experiencing it.
The legacy grudge. Prior conflicts between board members — a deal that went badly, a prior company where trust was damaged, a personal slight that was never directly addressed — create persistent distortions in board dynamics. A director who does not trust a fellow director will discount their analysis, resist their proposals, and find ways to limit their influence that feel, to the director employing them, like legitimate governance concerns rather than personal animus. These dynamics are particularly resistant to resolution because they are rarely named, and because naming them feels like a violation of the professional norms that govern board conduct.
The chair capture. In companies where the board chair is an investor-director — a common arrangement in venture-backed biopharma — the chair's dual role creates a structural opportunity for agenda capture. Meeting schedules, information packages, and discussion time allocations are all shaped by the chair, and a chair whose institutional interests are specific can use these controls to ensure that topics unfavorable to those interests receive less attention, less time, or less well-prepared discussion than topics that serve them.
What the Research Says — and What It Doesn't
There is a substantial body of research on board dynamics in public companies, and some of it is directly applicable to small biopharma boards. The evidence consistently shows that boards with genuine cognitive diversity — directors who think differently about problems, not merely directors who look different — make better decisions, particularly in conditions of uncertainty. It also shows that psychological safety within the board — the degree to which directors feel able to raise dissenting views without social or professional cost — is one of the strongest predictors of governance quality.
What the research largely does not capture is the specific texture of small-board politics in venture-backed settings, because this context is systematically underrepresented in governance research. Public company boards are heavily studied; private clinical-stage boards are almost entirely undocumented in the academic literature. Practitioners working in this space are largely on their own, drawing on experience rather than evidence.
The implication is that governance wisdom in this context is primarily transmitted through direct experience and professional networks — which means that most boards are navigating these dynamics without the benefit of frameworks that would help them recognize patterns and respond more effectively.
How the Chair Shapes — or Fails to Shape — the Room
The single most important lever for managing small-board politics is the chair. A chair who understands the dynamics in the room and actively manages them can significantly mitigate the governance costs of interpersonal conflict, alliance formation, and agenda capture. A chair who is either unaware of those dynamics or is themselves a participant in them will allow the politics to run unchecked.
Active management by the chair involves several specific practices. Before each meeting, it includes a conversation with each director — brief but genuine — about what is on their mind, what they are concerned about, and what they want to ensure gets addressed. This is not about pre-aligning votes; it is about understanding the relational landscape before walking into the room. In the meeting itself, it involves attention to who is speaking and who is not, resistance to the tendency for one or two voices to fill the available space, and a deliberate effort to draw out the perspectives of directors who are quiet — particularly when their silence might reflect discomfort rather than agreement. After the meeting, it includes a candid debrief with the CEO and, where appropriate, individual conversations with directors whose behavior in the meeting raised concerns.
A chair who is also an investor-director faces an additional obligation: to be transparent with themselves and with the board about when their institutional interests are influencing their management of the room. This is a difficult self-assessment, and most investor-directors who serve as chairs are not fully equipped to make it honestly. Where the tension is significant, a lead independent director who can call out the dynamic — privately, not publicly — provides an important governance backstop.
The CEO's Position in the Political Landscape
The CEO of a venture-backed biopharma company occupies an unusual position relative to small-board politics. They are the primary audience for the board's governance, and the board's effectiveness has a direct effect on their ability to lead the company. At the same time, they are not a neutral party — their relationships with individual directors, their preferences about strategic direction, and their interests in their own position all shape how they engage with board dynamics.
A CEO who is politically sophisticated understands that cultivating genuine relationships with each board member — not just with the ones they find most congenial — gives them a more stable governance environment. A CEO whose relationship with the board is primarily channeled through one or two allied directors has created a governance situation that is comfortable in the short term and fragile in any situation where those alliances are tested.
A CEO who uses board politics strategically — playing directors against each other, selectively controlling information flow to shape individual directors' views, or managing the agenda in ways that limit the board's ability to scrutinize unfavorable developments — is creating a governance pathology that will eventually produce a result they do not want. Boards that have been managed rather than informed tend to overcorrect when they recognize it, and the overcorrection rarely serves either the company or the CEO.
When the Politics Become Dysfunctional
There is a threshold beyond which small-board politics cease to be a management challenge and become a governance crisis. Boards cross this threshold when the interpersonal dynamics are actively preventing the company from making decisions it needs to make, when confidential information is being weaponized inside the boardroom or leaked outside it, when directors are refusing to engage with each other in ways that leave the board unable to function as a collective, or when the CEO has effectively lost the confidence of the board but no one is willing to initiate the governance process that would address it.
These situations require intervention from outside the existing board dynamic — either from a trusted independent director who has standing with all parties, from outside counsel who can clarify the governance obligations at stake, or, in the most severe cases, from the institutional investors whose financial interests are most directly harmed by a board that has ceased to function.
The intervention does not resolve the underlying relationship dynamics — those are often permanent features of the landscape. It addresses the immediate governance failure and creates a path back to functional decision-making, even if that path requires changes to board composition, leadership structure, or both.
The Governance Aspiration
The goal of managing small-board politics is not to eliminate conflict — conflict is often a sign that the board is doing its job. Directors who disagree about the right path forward, who scrutinize management's preferred interpretation of clinical data, who ask uncomfortable questions about capital allocation, are providing governance value precisely through that friction.
The goal is to ensure that the conflicts in the room are about the substance of what the company should do rather than about the politics of who has power and whose interests are being served. That distinction is not always easy to maintain in a small room where institutional interests and interpersonal histories are both present. But it is the distinction that separates a board that is genuinely governing from one that is performing governance while the real decisions happen somewhere else.
Building a board culture where that distinction holds requires sustained attention — from the chair, from the independent directors, and from the CEO. It is not achieved once and maintained automatically. It is earned, meeting by meeting, through the accumulated choices of people who understand what a functional board is supposed to do and who care enough about the company's mission to prioritize that over the comfort of unchallenged alliance.
Lawrence Fine is CEO of AGCP Farmacêuticos and has advised on board dynamics and governance structure across life sciences and advanced materials companies.